Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Paratek Sees Broad Potential For Omadacycline After Second Phase III Win

04 Apr 2017

• By Mandy Jackson

Antibiotic resistant bacteria closeup biofilm

Related Content

Paratek Antibiotic Meets Non-Inferiority Bar In First Phase III

17 Jun 2016

PIPELINE WATCH: Two Approvals, Two Filings And One Withdrawal

19 Aug 2016

Related Companies

Paratek Pharmaceuticals, Inc.

Pfizer Inc.

Melinta Therapeutics, Inc.

Additional Topics

Research & Development Clinical Trials Cost Effectiveness Drug Safety Infectious Diseases BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.